1. Wrong melanoma thickness measurement: check it or leave it?

  2. Topical cream delivers NB-UVB from sunlight for the treatment of vitiligo.

  3. The "mystery" of cutaneous sarcoidosis: facts and controversies.

  4. Outcompeting nitrite-oxidizing bacteria in single-stage nitrogen removal in sewage treatment plants: a model-based study.

  5. Simultaneous partial nitritation and anammox at low temperature with granular sludge.

  6. The role of neuropeptides in the control of regional immunity.

  7. Multiple primary cutaneous melanomas in patients with FAMMM syndrome and sporadic atypical mole syndrome (AMS): what's worse?

  8. In-vivo imaging of psoriatic lesions with polarization multispectral dermoscopy and multiphoton microscopy.

  9. Vitiligo: what's new in the psycho-neuro-endocrine-immune connection and related treatments.

  10. High prevalence of circulating autoantibodies against thyroid hormones in vitiligo and correlation with clinical and historical parameters of patients.

  11. Anammox growth on pretreated municipal wastewater.

  12. Hepato-splenic and lipid profile abnormalities--do they exist in children affected with vitiligo?

  13. Physiological and kinetic characterization of a suspended cell anammox culture.

  14. Novel topical cream delivers safe and effective alternative to traditional psoriasis phototherapy.

  15. Vitiligo as a systemic disease.

  16. Novel topical cream delivers safe and effective sunlight therapy for vitiligo by selectively filtering damaging ultraviolet radiation.

  17. SIRT1 regulates MAPK pathways in vitiligo skin: insight into the molecular pathways of cell survival.

  18. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry.

  19. In vivo non-invasive monitoring of collagen remodelling by two-photon microscopy after micro-ablative fractional laser resurfacing.

  20. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia.

  21. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT).

  22. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.

  23. In vitro evaluation of a novel topical cream for vitiligo and psoriasis that selectively delivers NB-UVB therapy when exposed to sunlight.

  24. Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study.


The Science & 

Mathematics University

  • Facebook Clean Grey
  • Twitter Clean Grey
  • LinkedIn Clean Grey

© 2023 by Scientist Personal. Proudly created with Wix.com